Vertex Pharmaceutic (VRTX) 94.51 $VRTX
Zacks.com featured highlights: Covanta Holding, ZELTIQ Aesthetics, Capital Senior Living, Live Nation Entertainment and Vertex Pharmaceuticals
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 8:30AM CDT
Zacks.com featured highlights: Covanta Holding, ZELTIQ Aesthetics, Capital Senior Living, Live Nation Entertainment and Vertex Pharmaceuticals
CSU: 17.19 (-0.26), CVA: 14.89 (+0.10), VRTX: 94.51 (-1.29), ZLTQ: 38.12 (-0.28), LYV: 26.72 (unch)
5 Toxic Stocks to Steer Clear Of Before It's Too Late
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 7:25AM CDT
Overpricing of toxic stocks can be ascribed to either an irrational exuberance associated with them or some serious fundamental drawbacks.
CVA: 14.89 (+0.10), CSU: 17.19 (-0.26), VRTX: 94.51 (-1.29), ZLTQ: 38.12 (-0.28), LYV: 26.72 (unch)
Stock Market News for August 25, 2016
Zacks Equity Research - Zacks Investment Research - Thu Aug 25, 8:55AM CDT
Benchmarks ended in the red on Wednesday following decline in Mylan’s shares, which had a negative impact on the biotech stocks and eventually on the broader healthcare sector
FIT: 15.48 (+0.11), ENDP: 20.70 (-0.19), VRTX: 94.51 (-1.29), GILD: 78.38 (+0.46), CEO: 120.09 (-1.77), MYL: 42.36 (-0.39), ILMN: 168.34 (-0.65), SDRL: 2.41 (-0.06), HPQ: 14.37 (-0.01), PVH: 107.76 (-0.16)
Vertex Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 2.89%
Comtex SmarTrend(R) - Mon Aug 22, 1:33PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $98.00 to a high of $101.80. Yesterday, the shares gained 2.9%, which took the trading range above the 3-day high of $100.36 on volume of 704,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VRTX: 94.51 (-1.29)
The Zacks Analyst Blog Highlights: Vertex, Aurinia, AVEO and Amgen
Zacks Equity Research - Zacks Investment Research - Thu Aug 18, 8:30AM CDT
The Zacks Analyst Blog Highlights: Vertex, Aurinia, AVEO and Amgen
VRTX: 94.51 (-1.29), AUPH: 1.94 (-0.01), AVEO: 0.93 (-0.02), AMGN: 170.06 (-0.70)
Biotech Stock Roundup: Vertex Slips on Study Halt, Aurinia Plunges on Lupus Data
Arpita Dutt - Zacks Investment Research - Wed Aug 17, 2:49PM CDT
With second quarter earnings season drawing to a close, focus in back on pipeline and regulatory updates.
BIIB: 305.63 (-2.23), VRTX: 94.51 (-1.29), AUPH: 1.94 (-0.01), OGXI: 0.54 (-0.03), GILD: 78.38 (+0.46), AVEO: 0.93 (-0.02), AMGN: 170.06 (-0.70)
TJX and Hain Celestial stumble, G&K Services surges
AP - Tue Aug 16, 3:57PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday:
KMI: 21.85 (-0.06), VRTX: 94.51 (-1.29), DKS: 58.60 (-0.20), GK: 97.33 (+0.06), PX: 122.04 (-0.48)
Vertex (VRTX) To Stop VX-661-Ivacaftor Study, Stock Down
Arpita Dutt - Zacks Investment Research - Tue Aug 16, 9:25AM CDT
Vertex's (VRTX) shares were down in pre-market trading on the company's announcement that it will be stopping one of the phase III studies on its VX-661-ivacaftor combination.
VRTX: 94.51 (-1.29), ANIP: 59.74 (-1.12), GERN: 2.69 (unch), ANIK: 47.24 (-0.21)
Vertex Pharmaceuticals Falls 2.65% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Wed Aug 10, 2:34PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $99.72 to a high of $102.78. Yesterday, the shares fell 2.7%, which took the trading range below the 3-day low of $99.77 on volume of 337,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
VRTX: 94.51 (-1.29)
Look for Shares of Vertex Pharmaceuticals to Potentially Rebound after Yesterday's 2.65% Sell Off
Comtex SmarTrend(R) - Wed Aug 10, 2:33PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $99.72 to a high of $102.78. Yesterday, the shares fell 2.7%, which took the trading range below the 3-day low of $99.77 on volume of 337,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
VRTX: 94.51 (-1.29)
Kroll Bond Rating Agency Assigns Preliminary Ratings to MSCI 2016-UBS11
BusinessWire - Mon Aug 08, 9:56AM CDT
Kroll Bond Rating Agency (KBRA) is pleased to announce the assignment of preliminary ratings to 16 classes of the MSCI 2016-UBS11 transaction. MSCI 2016-UBS11 is a $719.8 million CMBS conduit transaction collateralized by 38 commercial mortgage loans secured by 75 properties.
VRTX: 94.51 (-1.29)
Vertex Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 1.35%
Comtex SmarTrend(R) - Wed Aug 03, 1:43PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $99.12 to a high of $101.50. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $99.45 on volume of 684,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VRTX: 94.51 (-1.29)
Nivalis (NVLS) Reports Wider-than-Expected Loss in Q2
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 9:28AM CDT
Nivalis Therapeutics (NVLS) reported a wider-than-expected second-quarter 2016 loss of 55 cents per share.
VRTX: 94.51 (-1.29), ANIP: 59.74 (-1.12), NVLS: 6.39 (+0.08), ANIK: 47.24 (-0.21)
Ophthotech Announces Election of Ian F. Smith, Vertex Executive Vice President and Chief Financial Officer, to Its Board of Directors
BusinessWire - Tue Aug 02, 6:30AM CDT
Ophthotech Corporation (Nasdaq:OPHT) today announced the election of Ian F. Smith, Executive Vice President and Chief Financial Officer of Vertex Pharmaceuticals, to its Board of Directors, effective immediately. Mr. Smith has also been elected the Chair of the Ophthotech Audit Committee.
VRTX: 94.51 (-1.29), OPHT: 52.81 (-0.56)
Research Report Coverage on Select Biotech Stocks -- Vertex Pharma, Infinity Pharma, Aduro BioTech, and Aralez Pharma
PR Newswire - Mon Aug 01, 7:05AM CDT
The Biotech industry is where investors come out either short or confidently strong. Following its fall in September 2015, the industry is now signaling a pullback, suggesting to the investor community that buying opportunities are available. Additionally, the sector finished on a solid note in July 2016, up 10%. Today, Stock-Callers.com has the following equities on its radar for further assessment: Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), Infinity Pharmaceuticals Inc. (NASDAQ: INFI), Aduro BioTech Inc. (NASDAQ: ADRO), and Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ). These stocks research reports can be downloaded now by simply registering for free at:
VRTX: 94.51 (-1.29), ADRO: 14.09 (+0.14), ARLZ: 4.97 (-0.07), INFI: 1.52 (-0.08)
Vertex (VRTX) Posts Narrower Q2 Loss, Revenues Fall Short
Arpita Dutt - Zacks Investment Research - Thu Jul 28, 6:13AM CDT
Although total revenues were just shy of expectations, Vertex's (VRTX) CF franchise sales improved sequentially.
BIIB: 305.63 (-2.23), VRTX: 94.51 (-1.29), INVA: 11.09 (+0.08), ANIP: 59.74 (-1.12)
Nivalis (NVLS): Can the Stock Surprise This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 5:46PM CDT
Nivalis Therapeutics (NVLS), which is expected to report second-quarter 2016 results on Aug 1, posted a negative surprise of 15.91% last quarter.
VRTX: 94.51 (-1.29), NVLS: 6.39 (+0.08), UTHR: 122.28 (+0.37), BMY: 57.39 (+0.15)
Vertex Reports Second Quarter 2016 Financial Results
BusinessWire - Wed Jul 27, 3:01PM CDT
---Vertex reiterates 2016 guidance for ORKAMBI product revenues of $1.0 to $1.1 billion and KALYDECO product revenues of $685 to $705 million-
VRTX: 94.51 (-1.29)
Zacks.com featured highlights: Covanta Holding, ZELTIQ Aesthetics, Capital Senior Living, Live Nation Entertainment and Vertex Pharmaceuticals
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 8:30AM CDT
Zacks.com featured highlights: Covanta Holding, ZELTIQ Aesthetics, Capital Senior Living, Live Nation Entertainment and Vertex Pharmaceuticals
CSU: 17.19 (-0.26), CVA: 14.89 (+0.10), VRTX: 94.51 (-1.29), ZLTQ: 38.12 (-0.28), LYV: 26.72 (unch)
5 Toxic Stocks to Steer Clear Of Before It's Too Late
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 7:25AM CDT
Overpricing of toxic stocks can be ascribed to either an irrational exuberance associated with them or some serious fundamental drawbacks.
CVA: 14.89 (+0.10), CSU: 17.19 (-0.26), VRTX: 94.51 (-1.29), ZLTQ: 38.12 (-0.28), LYV: 26.72 (unch)
Stock Market News for August 25, 2016
Zacks Equity Research - Zacks Investment Research - Thu Aug 25, 8:55AM CDT
Benchmarks ended in the red on Wednesday following decline in Mylan’s shares, which had a negative impact on the biotech stocks and eventually on the broader healthcare sector
FIT: 15.48 (+0.11), ENDP: 20.70 (-0.19), VRTX: 94.51 (-1.29), GILD: 78.38 (+0.46), CEO: 120.09 (-1.77), MYL: 42.36 (-0.39), ILMN: 168.34 (-0.65), SDRL: 2.41 (-0.06), HPQ: 14.37 (-0.01), PVH: 107.76 (-0.16)
Vertex Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 2.89%
Comtex SmarTrend(R) - Mon Aug 22, 1:33PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $98.00 to a high of $101.80. Yesterday, the shares gained 2.9%, which took the trading range above the 3-day high of $100.36 on volume of 704,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VRTX: 94.51 (-1.29)
The Zacks Analyst Blog Highlights: Vertex, Aurinia, AVEO and Amgen
Zacks Equity Research - Zacks Investment Research - Thu Aug 18, 8:30AM CDT
The Zacks Analyst Blog Highlights: Vertex, Aurinia, AVEO and Amgen
VRTX: 94.51 (-1.29), AUPH: 1.94 (-0.01), AVEO: 0.93 (-0.02), AMGN: 170.06 (-0.70)
Biotech Stock Roundup: Vertex Slips on Study Halt, Aurinia Plunges on Lupus Data
Arpita Dutt - Zacks Investment Research - Wed Aug 17, 2:49PM CDT
With second quarter earnings season drawing to a close, focus in back on pipeline and regulatory updates.
BIIB: 305.63 (-2.23), VRTX: 94.51 (-1.29), AUPH: 1.94 (-0.01), OGXI: 0.54 (-0.03), GILD: 78.38 (+0.46), AVEO: 0.93 (-0.02), AMGN: 170.06 (-0.70)
TJX and Hain Celestial stumble, G&K Services surges
AP - Tue Aug 16, 3:57PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday:
KMI: 21.85 (-0.06), VRTX: 94.51 (-1.29), DKS: 58.60 (-0.20), GK: 97.33 (+0.06), PX: 122.04 (-0.48)
Vertex (VRTX) To Stop VX-661-Ivacaftor Study, Stock Down
Arpita Dutt - Zacks Investment Research - Tue Aug 16, 9:25AM CDT
Vertex's (VRTX) shares were down in pre-market trading on the company's announcement that it will be stopping one of the phase III studies on its VX-661-ivacaftor combination.
VRTX: 94.51 (-1.29), ANIP: 59.74 (-1.12), GERN: 2.69 (unch), ANIK: 47.24 (-0.21)
Vertex Pharmaceuticals Falls 2.65% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Wed Aug 10, 2:34PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $99.72 to a high of $102.78. Yesterday, the shares fell 2.7%, which took the trading range below the 3-day low of $99.77 on volume of 337,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
VRTX: 94.51 (-1.29)
Look for Shares of Vertex Pharmaceuticals to Potentially Rebound after Yesterday's 2.65% Sell Off
Comtex SmarTrend(R) - Wed Aug 10, 2:33PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $99.72 to a high of $102.78. Yesterday, the shares fell 2.7%, which took the trading range below the 3-day low of $99.77 on volume of 337,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
VRTX: 94.51 (-1.29)
Kroll Bond Rating Agency Assigns Preliminary Ratings to MSCI 2016-UBS11
BusinessWire - Mon Aug 08, 9:56AM CDT
Kroll Bond Rating Agency (KBRA) is pleased to announce the assignment of preliminary ratings to 16 classes of the MSCI 2016-UBS11 transaction. MSCI 2016-UBS11 is a $719.8 million CMBS conduit transaction collateralized by 38 commercial mortgage loans secured by 75 properties.
VRTX: 94.51 (-1.29)
Vertex Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 1.35%
Comtex SmarTrend(R) - Wed Aug 03, 1:43PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $99.12 to a high of $101.50. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $99.45 on volume of 684,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VRTX: 94.51 (-1.29)
Nivalis (NVLS) Reports Wider-than-Expected Loss in Q2
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 9:28AM CDT
Nivalis Therapeutics (NVLS) reported a wider-than-expected second-quarter 2016 loss of 55 cents per share.
VRTX: 94.51 (-1.29), ANIP: 59.74 (-1.12), NVLS: 6.39 (+0.08), ANIK: 47.24 (-0.21)
Ophthotech Announces Election of Ian F. Smith, Vertex Executive Vice President and Chief Financial Officer, to Its Board of Directors
BusinessWire - Tue Aug 02, 6:30AM CDT
Ophthotech Corporation (Nasdaq:OPHT) today announced the election of Ian F. Smith, Executive Vice President and Chief Financial Officer of Vertex Pharmaceuticals, to its Board of Directors, effective immediately. Mr. Smith has also been elected the Chair of the Ophthotech Audit Committee.
VRTX: 94.51 (-1.29), OPHT: 52.81 (-0.56)
Research Report Coverage on Select Biotech Stocks -- Vertex Pharma, Infinity Pharma, Aduro BioTech, and Aralez Pharma
PR Newswire - Mon Aug 01, 7:05AM CDT
The Biotech industry is where investors come out either short or confidently strong. Following its fall in September 2015, the industry is now signaling a pullback, suggesting to the investor community that buying opportunities are available. Additionally, the sector finished on a solid note in July 2016, up 10%. Today, Stock-Callers.com has the following equities on its radar for further assessment: Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), Infinity Pharmaceuticals Inc. (NASDAQ: INFI), Aduro BioTech Inc. (NASDAQ: ADRO), and Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ). These stocks research reports can be downloaded now by simply registering for free at:
VRTX: 94.51 (-1.29), ADRO: 14.09 (+0.14), ARLZ: 4.97 (-0.07), INFI: 1.52 (-0.08)
Vertex (VRTX) Posts Narrower Q2 Loss, Revenues Fall Short
Arpita Dutt - Zacks Investment Research - Thu Jul 28, 6:13AM CDT
Although total revenues were just shy of expectations, Vertex's (VRTX) CF franchise sales improved sequentially.
BIIB: 305.63 (-2.23), VRTX: 94.51 (-1.29), INVA: 11.09 (+0.08), ANIP: 59.74 (-1.12)
Nivalis (NVLS): Can the Stock Surprise This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 5:46PM CDT
Nivalis Therapeutics (NVLS), which is expected to report second-quarter 2016 results on Aug 1, posted a negative surprise of 15.91% last quarter.
VRTX: 94.51 (-1.29), NVLS: 6.39 (+0.08), UTHR: 122.28 (+0.37), BMY: 57.39 (+0.15)
Vertex Reports Second Quarter 2016 Financial Results
BusinessWire - Wed Jul 27, 3:01PM CDT
---Vertex reiterates 2016 guidance for ORKAMBI product revenues of $1.0 to $1.1 billion and KALYDECO product revenues of $685 to $705 million-
VRTX: 94.51 (-1.29)
